The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis

The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis

Introduction. The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a diseasemodifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One e...

Full description

Saved in:
Bibliographic Details
Main Authors: L. P. Ananyeva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoytova, O. A. Koneva, O. B. Ovsyannikova, S. I. Glukhova, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2023-08-01
Series:Научно-практическая ревматология
Subjects:
systemic sclerosis
rituximab
acellbia
Online Access:https://rsp.mediar-press.net/rsp/article/view/3403
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items